Propanc Biopharma (PPCB) Stock Overview
A development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PPCB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Propanc Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.51 |
| 52 Week High | US$145.46 |
| 52 Week Low | US$1.25 |
| Beta | 19205.45 |
| 1 Month Change | -72.11% |
| 3 Month Change | -55.02% |
| 1 Year Change | -91.62% |
| 3 Year Change | -100.00% |
| 5 Year Change | -99.86% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| PPCB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.6% | 1.2% | -0.6% |
| 1Y | -91.6% | -6.4% | 18.1% |
Return vs Industry: PPCB underperformed the US Biotechs industry which returned -6.6% over the past year.
Return vs Market: PPCB underperformed the US Market which returned 17.5% over the past year.
Price Volatility
| PPCB volatility | |
|---|---|
| PPCB Average Weekly Movement | 67.9% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PPCB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PPCB's weekly volatility has decreased from 83% to 68% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2 | James Nathanielsz | www.propanc.com |
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP.
Propanc Biopharma, Inc. Fundamentals Summary
| PPCB fundamental statistics | |
|---|---|
| Market cap | US$34.84m |
| Earnings (TTM) | -US$55.21m |
| Revenue (TTM) | n/a |
Is PPCB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PPCB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$55.21m |
| Earnings | -US$55.21m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.33 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 6.9% |
How did PPCB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/03 18:25 |
| End of Day Share Price | 2025/09/03 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Propanc Biopharma, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ajay Tandon | SeeThruEquity, LLC |